ALNOV NOVACYT LONG
LONG TERM ANALISIS
It is at an important support in the long term and will reach significant resistance.
In Spain on 3/05/2022
13.34 MEUR
70.47 M
About NOVACYT
Sector
Industry
CEO
James Martin McCarthy
Website
Headquarters
Vélizy-Villacoublay
Founded
2006
ISIN
FR0010397232
FIGI
BBG003CDTG68
Novacyt SAS is a diagnostics company, which engages in the business of developing, producing, and selling vitro and molecular diagnostic tests and products for a wide range of infectious diseases. It operates through the following segments: Primer Design, IT-IS International, and Corporate. The Primer Design segment focuses on the activities of Primer Design Ltd, which is a designer, manufacturer, and marketer of molecular real-time qPCR testing devices and reagents. The IT-IS International segment is involved in IT-IS International Ltd, a diagnostic instrument development and manufacturing company specializing in the development of PCR devices for the life sciences and food testing industry. The Corporate segment includes group central and corporate costs. The company was founded by Eric Peltier, Gerald Ulrich, and Jean-Pierre Crinelli on July 3, 2006 and is headquartered in Velizy-Villacoublay, France.
Novacyt ALNOV They have at their disposal the technical analysis of Novacyt, it has great bullish potential, they have marked resistance and support.
I hope it will help you.
Sincerely, L.E.D. In Spain on 01/20/2022
Novacyt ALNOV They have marked the supports and resistances of ALNOV .
It has great upside potential, key level reaching $ 5
Last Friday news Clinical diagnostics specialist Novacyt announced on Friday thatots ‘genesig’ Covid-19 real-time PCR test has been approved in the UK. Great news and great upside potential
Novacyt ALNOV They have marked the supports and resistances of ALNOV.
It has great upside potential, key level reaching $ 5
Last Friday news Clinical diagnostics specialist Novacyt announced on Friday thatots ‘genesig’ Covid-19 real-time PCR test has been approved in the UK.
I send you a cordial greeting, Merry
Novacyt ALNOV Graham Mullis, CEO of the Novacyt Group, commented:
“Novacyt continues to process COVID-19 tests for current and future demand. We continue to ensure that innovation is at the center of our strategy and that our growing portfolio of COVID-19 tests is available to clients in private and public health
Novacyt NCTY what a pump !As you can see from the chart Novacyt had a massive volume inflow in the last 2 days even because of the very good news regarding the uk gov that accepted different NCTY covid tests and even because of the news of the new covid variant.
If you check my previous analysis I was waiting for a reversal
NCYT possible reversal pattern . I'm still bullish on this group,
I believe that the price will soon touch the support at 200 and get some high volume in and reverse the pattern getting back at some point to 500 zone.
( feel free to comment , I've just started to analise the graphs, any suggestions or critics are really apprecia
ALNOV Novacyt Graham Mullis, Group CEO of Novacyt, commented:
“Novacyt is continuing to address COVID-19 testing for both current and future demand. We continue to ensure that innovation is at the centre of our strategy and that our growing portfolio of COVID-19 tests are available to customers in both private an
ALNOV NOVACYT Novacyt big fall today, don't worry medium long term still hasn't broken level but keep an eye out for volatility next week we recommend that you buy if you can to the level you think is appropriate, it is a company that in the medium term has high expectations L.E.D Capital Management has investmen
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ALNOV is 0.632 EUR — it has decreased by 4.39% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange NOVACYT stocks are traded under the ticker ALNOV.
NOVACYT is going to release the next earnings report on Sep 26, 2024. Keep track of upcoming events with our Earnings Calendar.
NOVACYT revenue for the last quarter amounts to 63.19 M EUR despite the estimated figure of 94.71 M EUR. In the next quarter revenue is expected to reach 19.47 M EUR.
Yes, you can track NOVACYT financials in yearly and quarterly reports right on TradingView.
Like other stocks, ALNOV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOVACYT stock right from TradingView charts — choose your broker and connect to your account.